Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)
暂无分享,去创建一个
R. Tubiana | C. Katlama | L. Mandelbrot | G. Peytavin | C. Clavel | F. Bissuel | C. Crenn-Hébert | A. Marcelin | C. Soulié | H. Ichou | I. Heard | C. Ferreira
[1] V. Calvez,et al. Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy , 2010, Antimicrobial Agents and Chemotherapy.
[2] C. Delaugerre,et al. High Concentration of Raltegravir in Semen of HIV-Infected Men: Results from a Substudy of the EASIER-ANRS 138 Trial , 2009, Antimicrobial Agents and Chemotherapy.
[3] B. Damle,et al. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.
[4] C. Pasquier,et al. Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy , 2009, Journal of Clinical Microbiology.
[5] H. Teppler,et al. Effects of omeprazole on plasma levels of raltegravir. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] F. Brun-Vézinet,et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. , 2008, The Journal of antimicrobial chemotherapy.
[7] C. Rouzioux,et al. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. , 2008, The Journal of antimicrobial chemotherapy.
[8] J. Hogan,et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. Wagner,et al. Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.
[10] B. Jung,et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.
[11] Myron S. Cohen,et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis , 2007, AIDS.
[12] A. Molinari,et al. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein , 2007, Retrovirology.
[13] K. Anastos,et al. HIV-1 drug resistance in variants from the female genital tract and plasma. , 2007, The Journal of infectious diseases.
[14] C. Kovacs,et al. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.
[15] A. Caliendo,et al. Differences in HIV-1 pol Sequences From Female Genital Tract and Blood During Antiretroviral Therapy , 2003, Journal of acquired immune deficiency syndromes.
[16] M. Kazatchkine,et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. , 2000, The Journal of infectious diseases.
[17] A. Caliendo,et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA , 2000, AIDS.